Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Eli Lilly to acquire Phase 1/2 DICE Thera for US$2.4 Billion

<< Previous

Bullboard Posts

Next >>

Comment by fox7mfon Jul 25, 2023 3:01pm

168 Views

Post# 35556427

RE:RE:RE:RE:RE:Eli Lilly to acquire Phase 1/2 DICE Thera for US$2.4 Billion

Hope that wasn't directed at me. I'm just posting the facts around those buyouts. I, like many others, see a lot of validity behind your $10b-$15b projections for an $Oncy buyout. I actually think there is an argument for an Immunomedics type number...Pela is going to make some BP a lot of $$$$ in many different indications.

<< Previous

Bullboard Posts

Next >>

dynaCERT leans into global growth with new HydraGEN orders